Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: VERE THER

Market Cap 994M 867M 803M 752M 1.41B 93.81B 1.42B 9.52B 3.69B 46.17B 3.73B 3.65B 160B P/E 2023
-4.47x
P/E 2024 -2.4x
Enterprise Value 540M 471M 436M 408M 765M 50.94B 770M 5.17B 2B 25.07B 2.03B 1.98B 87.06B EV / Sales 2023
46,430,598x
EV / Sales 2024 717,743x
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 year 10.9
Extreme 10.9
11.34
3 years 2.86
Extreme 2.8647
21.04
5 years 2.86
Extreme 2.8647
78
10 years 2.86
Extreme 2.8647
78
Manager TitleAgeSince
President - 25/07/2025
Date Insider Type Main position Quantity % Market Cap.
25/07/25Tender

Chief Technology Officer

538,331 0.6358%
25/07/25Tender

Founder

3,397,141 4.0125%
25/07/25Issuer sale

Director

309,741 0.3658%

Financials

2023 2024
Net sales 11.76 10.25 9.49 8.89 16.67 1.11K 16.77 112.64 43.65 546.09 44.14 43.19 1.9K 32.33 28.19 26.11 24.44 45.84 3.05K 46.12 309.73 120.04 1.5K 121.36 118.76 5.21K
Net income -200M -174M -162M -151M -284M -18.88B -285M -1.92B -743M -9.29B -751M -735M -32.26B -199M -173M -160M -150M -282M -18.75B -283M -1.9B -738M -9.23B -746M -730M -32.05B
Net Debt -549M -479M -443M -415M -778M -51.81B -783M -5.26B -2.04B -25.5B -2.06B -2.02B -88.54B -454M -396M -367M -343M -644M -42.87B -648M -4.35B -1.69B -21.1B -1.71B -1.67B -73.26B
Logo VERE THER
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Employees
274
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. VERV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!